<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01416324</url>
  </required_header>
  <id_info>
    <org_study_id>114985</org_study_id>
    <nct_id>NCT01416324</nct_id>
  </id_info>
  <brief_title>First Time in Human Study Using GSK2330672</brief_title>
  <official_title>A First Time in Human, Single Blind, Randomized, Placebo-controlled,Dose Escalating Crossover Study to Evaluate the Safety,Tolerability, Pharmacokinetic and Pharmacodynamic Parameters of Single Doses of GSK2330672 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at the safety and tolerability of increasing single
      doses of GSK2330672 in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single blind, randomized, placebo-controlled, dose escalating, crossover, first
      time in human study to examine safety, tolerability, pharmacokinetic and pharmacodynamic
      parameters of GSK233672. Single blind indicates that the subjects and investigator are
      blinded to treatment but the GSK study team could be unblinded for ongoing review of interim
      safety data required for dose escalation.

      Subjects will participate in 4 dosing periods. Subjects will enter the clinic prior to dinner
      time on the evening of Day -1 of each period and will remain in residence through the morning
      of Day 3. Barring any safety or tolerability concerns, subjects will be released at this time
      provided they have had at least 1 bowel movement after dosing in the clinic.

      Subjects will return for their next scheduled dosing period. This process will be repeated
      for each dosing period. Subjects will return approximately 1 week after check out from their
      last dosing period for a follow up visit. Subjects will receive standardized meals meeting
      specific criteria starting with dinner on Day-1 and continuing through Day 1. Standard meals
      will be provided for the remainder of their stay in the clinic. After an overnight fast,
      subjects will take their study drug on the morning of Day 1. Dosing will be followed by
      breakfast and frequent blood sampling to assess pharmacokinetic and pharmacodynamic
      parameters. Scheduled assessments of heart rate, blood pressure, respiratory rate, ECGs, and
      clinical laboratories will be obtained to monitor subject safety. Subjects will be connected
      to cardiac telemetry monitors and will periodically undergo spirometry testing of ventilation
      parameters. Stool form and frequency of bowel movements will be recorded. All fecal samples
      will be collected from participants for 48 hours after dosing of study drug, or until they
      have had at least 1 bowel movement after dosing, whichever occurs first.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2011</start_date>
  <completion_date type="Actual">September 9, 2011</completion_date>
  <primary_completion_date type="Actual">September 9, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in vital signs</measure>
    <time_frame>1, 2, 4, 8, 12, 24, 48 hours</time_frame>
    <description>frequency and absolute value change in heart rate, blood pressure, respiration rate relative to placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECGs relative to placebo</measure>
    <time_frame>1, 2, 4, 8, 12, 24, 48 hours</time_frame>
    <description>frequency of clinically significant changes in 12-lead ECG parameters relative to placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in clinical lab results</measure>
    <time_frame>24 hours</time_frame>
    <description>Changes in clinical chemistry, hematology, urinalysis results relative to placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>lung function tests</measure>
    <time_frame>1, 3, 8, 24 hours</time_frame>
    <description>Measure changes in FEV, FVC, FEF 25-75%, PEFR relative to placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events relative to placebo</measure>
    <time_frame>48 hour monitoring</time_frame>
    <description>Frequency and severity of adverse events relative to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of the maximum concentration (Cmax) for study drug</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of the time to achieve maximum concentration (tmax) for study drug</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of area under the curve (AUC) for study drug</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of half life (t 1/2) of study drug</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of apparent clearance (CL/F) of the study drug</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of the apparent volume of distribution (V/F) of the study drug</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>GSK2330672</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>experimental study drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Vehicle used to dilute the powder for oral administration.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1 mg GSK2330672</intervention_name>
    <description>GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.</description>
    <arm_group_label>GSK2330672</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3 mg GSK2330672</intervention_name>
    <description>GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.</description>
    <arm_group_label>GSK2330672</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 mg GSK2330672</intervention_name>
    <description>GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.</description>
    <arm_group_label>GSK2330672</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 mg GSK2330672</intervention_name>
    <description>GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.</description>
    <arm_group_label>GSK2330672</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg GSK2330672</intervention_name>
    <description>GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.</description>
    <arm_group_label>GSK2330672</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mg GSK2330672</intervention_name>
    <description>GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.</description>
    <arm_group_label>GSK2330672</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>60 mg GSK2330672</intervention_name>
    <description>GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.</description>
    <arm_group_label>GSK2330672</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteer

          -  18-60 yrs of age

          -  for subjects age 50 and above: negative fecal occult blood test within 3 months prior
             to expected start of dosing, and normal results from sigmoidoscopy or colonoscopy
             within 5 yrs prior to dosing.

          -  if female, must be of non-childbearing potential

        Exclusion Criteria:

          -  pregnant or breastfeeding females

          -  positive HIV

          -  positive Hep B, or Hep C within 3 months of screening

          -  positive drugs of abuse screening

          -  triglycerides &gt; 250 mg/dL

          -  current or chronic history of liver disease

          -  any gastrointestinal or gastrointestinal related conditions that could affect fat or
             bile acid reabsorption

          -  pancreatitis

          -  colon cancer or 1st degree relative who has had colon cancer

          -  abnormal lung function tests

          -  inability to perform lung function tests

          -  unwilling to abstain from smoking, alcohol, caffeine, illicit drugs as directed by the
             site staff

          -  exposure to more than 4 new chemical entities in the 12 months prior to the first
             dosing day.

          -  where participation in the study would results in donation of more than approximately
             550mL of blood in a 56-day period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/114985?search=study&amp;search_terms=114985#rs</url>
    <description>Results for study 114985 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2011</study_first_submitted>
  <study_first_submitted_qc>August 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2011</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacodynamics</keyword>
  <keyword>first time in human</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>114985</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114985</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114985</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114985</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114985</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114985</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114985</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

